Sangamo Therapeutics (SGMO) Non-Current Receivables (2023 - 2025)
Historic Non-Current Receivables for Sangamo Therapeutics (SGMO) over the last 3 years, with Q3 2025 value amounting to $14.5 million.
- Sangamo Therapeutics' Non-Current Receivables changed N/A to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year change of. This contributed to the annual value of $12.8 million for FY2024, which is 1661.89% down from last year.
- According to the latest figures from Q3 2025, Sangamo Therapeutics' Non-Current Receivables is $14.5 million.
- In the past 5 years, Sangamo Therapeutics' Non-Current Receivables ranged from a high of $15.4 million in Q4 2023 and a low of $12.8 million during Q4 2024
- In the last 3 years, Sangamo Therapeutics' Non-Current Receivables had a median value of $14.5 million in 2025 and averaged $14.1 million.
- Within the past 5 years, the most significant YoY rise in Sangamo Therapeutics' Non-Current Receivables was 1661.89% (2024), while the steepest drop was 1661.89% (2024).
- Quarter analysis of 3 years shows Sangamo Therapeutics' Non-Current Receivables stood at $15.4 million in 2023, then dropped by 16.62% to $12.8 million in 2024, then increased by 13.0% to $14.5 million in 2025.
- Its Non-Current Receivables was $14.5 million in Q3 2025, compared to $14.5 million in Q2 2025 and $13.3 million in Q1 2025.